Although mitochondrial DNA has been implicated in diseases such as cancer, its role remains to be defined. Using three models of tumorigenesis, namely glioblastoma multiforme, multiple myeloma and osteosarcoma, we show that mitochondrial DNA plays defining roles at early and late tumour progression. Specifically, tumour cells partially or completely depleted of mitochondrial DNA either restored their mitochondrial DNA content or actively recruited mitochondrial DNA, which affected the rate of tumorigenesis. Nevertheless, non-depleted tumour cells modulated mitochondrial DNA copy number at early and late progression in a mitochondrial DNA genotype-specific manner. In glioblastoma multiforme and osteosarcoma, this was coupled with loss and gain of mitochondrial DNA variants. Changes in mitochondrial DNA genotype affected tumour morphology and gene expression patterns at early and late progression. Importantly, this identified a subset of genes that are essential to early progression. Consequently, mitochondrial DNA and commonly expressed early tumour-specific genes provide novel targets against tumorigenesis.
INTRODUCTION
The human mitochondrial genome (mtDNA) is 16.6 kb in size, circular and encodes 13 key genes of the electron transfer chain (ETC), which generates the vast majority of cellular ATP through the process of oxidative phosphorylation (OXPHOS). 1 It also encodes 22 tRNAs and 2 RNAs and has one non-coding region, the D-loop. Disruption of the ETC due to mutation, deletion or depletion of mtDNA is associated with an increasing number of diseases. 2 Although mtDNA copy number and variants have been associated with cancer, 3, 4 it remains to be determined whether the regulation of mtDNA copy number and the ability of mtDNA to acquire de novo variants are instrumental in driving tumorigenesis and, if so, how they affect the tumour phenotype. To test this, we have used three independent experimental models consisting of glioblastoma multiforme (GBM), a primary brain tumour that is neural in origin and a solid tumour; 5 multiple myeloma (MM), a haematological tumour that originates from terminally differentiated B cells; 6 and osteosarcoma, a solid tumour originating from osteoblast precursors. 7 We show that mtDNA is essential for driving tumorigenesis and that complete mtDNA depletion prevents the onset of tumorigenesis. Furthermore, mtDNA copy number and variants are modulated at different stages of tumorigenesis. Altering a tumour cell's mtDNA content results in changes to nuclear gene expression that directly affect the severity of the tumour phenotype.
RESULTS

Modulating mtDNA copy number in MM cells disrupts tumorigenesis
To determine whether haematological tumours are dependent on mtDNA for tumorigenesis, we depleted human MM U266 cells labelled with luciferase to 10% (U266 10 ), 0.12% (U266 0.12 ), 0.05% (U266 0.05 ) and 0.04% (U266 0.04 ) of their original mtDNA content (U266 100 ; Figure 1a ) and transplanted them and non-depleted (U266 100 ) cells into immunocompromised mice. After 35 days, each inoculation of U266 100 cells developed into tumours ( Figure 1b ) and, by 77 days, had spread to the hindlimbs causing paralysis, as anticipated. 8 Although U266 10 cells produced tumours in each mouse by 42 days (Figure 1b) , tumours grew at a significantly slower rate ( Figure 1c ) and their localization was less focal. At 84 days, only 20% of the mice developezd hindlimb paralysis. Nevertheless, U266 10 tumours recovered mtDNA copy number to levels similar to U266 100 tumours ( Figure 1d ). However, tumours did not arise from U266 0.12 , U266 0.05 and U266 0.04 cells (Figures 1b and c) . These results, along with the previous findings in our GBM tumour model, 9 suggest that a cell-specific threshold of mtDNA copy number is essential for the propagation and growth of tumours in solid and now blood cancers.
Tumour cells unable to replenish mtDNA recruit mtDNA Since partially mtDNA-depleted tumour cells replenish their mtDNA to initiate tumorigenesis, we inoculated immunocompromised mice with human osteosarcoma cells, 143BTK − , that were completely depleted of and unable to replenish mtDNA (143B   0   ) . 10, 11 While their non-depleted (143B 100 ) counterparts started to develop tumours 9 days post-inoculation and reached late progression (~800 mm 3 ) by day 25, tumour development in 143B 0 cells was initiated in only 60% of mice by day 59 and progressed at a much slower rate (Figure 2a ). Although 143B 100 tumours possessed mtDNA at preinoculation levels, 143B 0 tumours were unable to recover their endogenous mtDNA (Figure 2b ). However, 143B 0 tumour cells, FACS-sorted to eliminate contaminating mouse stroma, possessed mouse mtDNA (143B Mus ; Figure 2c ) most likely acquired from the surrounding in vivo microenvironment. 12 Colonies established from FACS-sorted single cells possessed~1 copy per cell (Figure 2d; 143 Mus clones). However, as human nuclear mtDNA replication factors cannot recognize murine mtDNA promoters, 13 mtDNA is recruited prior to early progression (~50 mm 3 ) and is thus diluted out by late progression (Figure 2d ). Consequently, 143B
Mus cells were reinoculated into mice to determine whether cells already harbouring more genetically divergent mtDNA would support full tumour development and acquire additional mtDNA. All five mice developed tumours; however, only one proceeded to late progression and had accelerated growth (Figure 2e ). The other four mice developed tumours to~200-300 mm 3 , which then arrested and ultimately regressed. Furthermore, tumours from reinoculated 143B
Mus cells possessed significantly higher levels of mtDNA (Figure 2d ), again indicating that mtDNA is acquired to sustain tumorigenesis. Collectively, these results demonstrate that mtDNA is essential to the onset of tumorigenesis and mtDNA is acquired from the surrounding tumour environments when endogenous mtDNA is unavailable. Figure S1 ). MtDNA copy number was higher in 143B 100 and 143B NSC cells than that of 143B GBM cells (Figure 2b ). To assess the tumorigenic potential of cells harbouring different mtDNA genotypes, mice were inoculated with 143B NSC and 143B GBM cells, which developed into tumours during the first 20 days. Tumours derived from 143B NSC cells had marginally slower growth rates than from 143B 100 cells, while tumours from 143B GBM cells grew more slowly than 143B 100 and 143B NSC cells (Figure 2a ). During tumorigenesis, mtDNA copy number was modulated according to the stage of development. 143B 100 cells reduced mtDNA copy number at early progression but reverted to preinoculated levels by late progression (Figure 2b ), similar to MM tumours ( Figure 1d ) derived from depleted cells. However, 143B
NSC and 143B GBM tumours had significantly higher levels of mtDNA copy number at early and late progression (Figure 2b ; Po 0.05). As mtDNA copy number is regulated in a tissue-specific manner by DNA methylation at exon 2 of the nuclear-encoded catalytic subunit of the mtDNA-specific Polymerase Gamma (POLGA), 14, 15 we assessed the mtDNA replicative efficiency in preinoculated cells and at early and late progression. As demonstrated by the distinct patterns of clustering for the three cohorts (Figure 2f ), mtDNA copy number is differentially regulated at various stages of tumorigenesis, mediated by DNA methylation at exon 2 of POLGA. These outcomes emphasize the plasticity of mtDNA copy number and DNA methylation of POLGA at exon 2 to promote tumorigenesis with adaptation of mtDNA copy number dependent on genotype.
Haematoxylin and eosin staining showed distinctive phenotypes between each of the tumours harbouring different mtDNA genotypes. Similar to 143B 100 tumours, 143B NSC tumours were predominantly sarcomatoid in appearance but exhibited focal regions of polygonal cell morphology consistent with a carcinoma phenotype (Supplementary Extended Data Figures S2a and b) , indicative of mesenchymal-epithelial transition (MET) and increased invasiveness. Figure S2f ). Consequently, mtDNA content induces phenotypic differences in tumours.
Different regions of mtDNA are susceptible to variants in MM and HSR-GBM1 tumours Since tumours harbour a range of mtDNA variants, 17 we assessed mtDNA next generation sequences from tumours generated from our GBM and MM models to determine which regions of mtDNA were more susceptible to the accumulation of variants. While HSR-GBM1 cells were most susceptible to mtDNA variants in COX2 (complex IV of the ETC) and the D-Loop for the coding and noncoding regions, respectively, tumours derived from HSR-GBM1 cells possessing either 100% mtDNA or depleted to varying levels 9 gained variants as a result of tumour formation 18 (Supplementary Extended Data Table S1 ). As a result, ND6 (complex I) became the most susceptible coding region to variants. In similar fashion, ATP8 and the D-Loop were the most susceptible to variants in U266 100 cells (Supplementary Extended Data Table S2 ). However, U266 10 cells and tumours derived from U266 100 and U266 10 cells resulted in ND6 being the most susceptible gene region most likely arising from an overall loss of variants in the coding regions during tumorigenesis and the gain of three de novo variants including the variant at position 14505 (ND6). Consequently, ND6 appears to be a highly susceptible region in tumours of solid and blood origin (Supplementary Extended Data Tables S1 and S2).
Changes in susceptibility to mtDNA variants at early and late progression To determine whether mtDNA variants were modulated during tumorigenesis, we assessed variants in our osteosarcoma model. For 143B 100 cells, the number of variants decreased from 18 to 10 as they proceeded to early progression and increased to 15 at late progression (Supplementary Extended Data Table S3 ). There were five common variants at all stages, two in the D-Loop and three in the coding regions. A further four variants were present in the coding regions of cells and at late progression but not at early progression. Nevertheless, as for MM and GBM, ND6 was the most susceptible to variants in cells and at late progression while ATP8 was the most susceptible at early progression. Similar patterns of modulation were observed for our 143B GBM 100 , 143B GBM and 143B NSC tumours at early and late progression underwent immunoprecipitation to assess the levels of enrichment for 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC), which are indicative of active de novo and transient DNA methylation, respectively, and mtDNA copy number to determine the replicative efficiency (*P o0.05; ***P o0.001).
with ATP8 being the most susceptible at these stages. Only 10 variants were identified in 143B NSC cells; however, at early progression, this was reduced to 6 followed by an increase to 14 at late progression (Supplementary Extended Data Table S3 ). Eight variants were common to cells and late progression. As a result, ND3 was the most susceptible to variants in cells and late progression while COX2 was the most susceptible at early progression. This highlights the dynamic nature of the recruitment of mtDNA variants during tumorigenesis. However, changing mtDNA genotypes results in different mtDNA coding genes becoming more susceptible to variants.
MtDNA copy number, variants and genotype modulate osteosarcoma gene expression The 143B cell lines and tumours were analysed by a wholegenome expression microarray to determine how mtDNA genotypes influence chromosomal gene expression during tumorigenesis, especially as certain mtDNA haplotypes are predisposed to cancer. 19, 20 There were 951 genes differentially expressed between the 143B 100 and 143B 0 tumours at late progression. The three most affected networks were: (1) nervous system development and function, drug metabolism and molecular transport; (2) RNA post-transcriptional modification, infectious disease and haematological disease; (3) and cellular assembly and organization, cellular function and maintenance, and connective tissue development and function (Supplementary  Table S1 ). Specifically, the hepatic fibrosis, RhoGDI signalling, mitochondrial function and angiogenesis pathways were significantly downregulated in 143B 0 tumours (Supplementary Extended Data Table S4 ). This was supported by upregulation of NFKB1A and NFKB1Z, which inhibit NF-κB activity and suppress proangiogenic molecules such as MMP9, 21, 22 and are associated with Figure 3 . Figure 3 . Network analysis based on differentially expressed genes between 143BNSC and 143BGBM tumours in (a) cancer, cardiovascular system development and function, and organismal development, (b) cancer, gastrointestinal disease and hepatic system disease, and (c) cell cycle, cardiovascular system development and function networks (red -upregulated in 143BNSC; green -downregulated in 143BNSC, fold change 42, P o0.05).
osteosarcoma. 23 Likewise, other immune-related genes, CXCL8, IL4R and IL10, were upregulated to promote cytokine responses and suppress tumorigenesis. Furthermore, genes regulating insulin-like growth factor action and bone formation were downregulated in 143B 0 tumours. By comparing 143B
GBM and 143B NSC with 143B 0 at late progression, we identified 379 differentially expressed genes. The three most affected networks were: (1) carbohydrate metabolism, amino acid metabolism and post-translational modification; (2) cellular development, haematological system development and function and hematopoiesis; (3) and connective tissue disorders, cardiovascular system development and function, and cellular development (Supplementary Table S2 ). Again, the majority of genes affected were associated with hepatic fibrosis and RhoGDI signalling (Supplementary Extended Data Table S4 ). Genes upregulated in the 143B NSC and 143B GBM tumours included those involved in glycolysis, highlighting the importance of this metabolic pathway to tumorigenesis. Among the genes involved in the hepatic fibrosis pathway, expression of the IGFBPs, COL4A1, COL4A2, MMP9 and TNFRSF11B was restored in 143B NSC and 143B GBM tumours. Furthermore, Cadherin-11 (CDH11), a marker of MET in osteosarcoma, 24 was upregulated in 143B GBM and 143B NSC tumours, indicating partial differentiation and metastasis. These outcomes indicate that the introduction of mtDNA activates key gene pathways to promote tumorigenesis. We identified 24 differentially expressed genes between the 143B NSC and 143B GBM tumours. The affected networks were Table S5 ). Neural lineage markers, such as NCAM1 (early) and NPTX1 (neuronal), were highly expressed in 143B NSC tumours, whereas genes involved in cancer proliferation, including EYA2, VCAN, HMGA1 and TXNIP, were highly expressed in 143B GBM tumours. The affected pathways were associated with adipogenesis, hepatic fibrosis and osteoblast formation (Supplementary Table S3 ). This highlights the cell-specific induction of nuclear gene expression at late progression by different mtDNA genotypes.
To determine whether gene expression patterns were differentially regulated by mtDNA genotypes at different stages of tumour development, we analysed gene expression patterns in 143B GBM and 143B
NSC tumours at early and late progression. We identified 33 differentially expressed genes between early and late 143B NSC tumours (Supplementary Table S4 ) and 30 for the 143B GBM tumours (Supplementary Table S5 ). Furthermore, 16 genes were upregulated in both the early 143B GBM and 143B NSC tumours and downregulated at late progression (Figure 4a ; P o 0.05, qo 0.05). Among the common genes, there were 4 functional genes, namely RPL21, RPL10A, CLEC2D and GOLIM4; and 10 pseudogenes, 7 for RPL21, and 1 each for RPL12, RPL36A and FTL.
Since RPL21 and RPL10A are highly expressed in cancer, 25, 26 we confirmed their upregulation in our model of tumorigenesis. RPL10A and RPL21 were more highly expressed in the 143B 100 , 143B
GBM and 143B NSC cell lines than human calvarial osteoblasts (HCO) (Figures 4b and c ; Po 0.01). There was no significant difference for RPL21 expression amongst 143B 100 , 143B GBM and 143B NSC cells and early progression, but expression was significantly higher at early than at late progression (Figure 4g ; Po 0.05). RPL10A expression was significantly elevated during early 143B 100 , 143B NSC and 143B GBM progression (Figure 4f ; P o 0.001). Expression of CLEC2D, which encodes lectin-like transcript 1 (LLT1) and blocks osteoclast differentiation, 27 was only significantly increased in the 143B 0 and 143B GBM cells when compared with HCO ( Figure 4d ; P o 0.001). However, expression of CLEC2D was significantly upregulated at early progression compared with late progression (Figure 4h ; P o0.05). Expression of GOLIM4, a Golgi integral membrane protein, was lower in tumour cells compared with HCO (Figure 4e ; P o 0.001), and upregulated in 143B 100 , 143B NSC and 143B GBM tumours at early progression (Figure 4i ; Po 0.001) and downregulated at late progression (Figure 4i ; Po 0.001). Therefore, by modulating mtDNA genotypes in tumour cells, we have identified a common core of essential genes specific to early progression.
Modulating mtDNA copy in MM cells affects tumorigenic gene expression To determine whether modulation of mtDNA copy number in tumour cells induces changes to gene expression, we performed RNA-seq on U266 100 and U266 10 cells and tumours. Between U266 100 and U266 10 cells, 16 genes were differentially expressed primarily affecting the cellular development, haematological system development and function, and hematopoiesis; connective tissue disorders; and developmental disorder networks (Supplementary Table S6 ). The canonical interferon signalling pathway was most affected, with type I interferon-related genes IFIT1, MX1, IFIT5 and ISG15 significantly downregulated in U266 10 cells along with the prosurvival gene NR4A2, which suppresses the assembly of tumour suppressor P53 28, 29 (Figure 5a ; Po0.05). Furthermore, MIR-663 was upregulated in U266 10 cells (Figure 5a ). MIR-663 targets TGFB1 and regulates the expression of PTEN, a tumour suppressor gene 30 and downregulates BCL-2 to induce apoptosis. 31 Consequently, in U266 cells, mtDNA depletion significantly decreases the expression of interferon-related genes, reduces P53 suppressor activity and activates tumour-suppressing micro-RNAs, which alter the tumorigenic state of U266 cells. However, in U266 10 tumours, gene expression was restored as a consequence of replenishing mtDNA, as only a few differentially regulated genes were identified that affected the post-translational modification, protein folding, cancer, cellular assembly and organization networks (Supplementary Extended Data Table S6 ). Primarily, HSPA1A, HSPA1B and ITM2C were upregulated (Figure 5b ; Po0.05), which alter the expression of heat-shock protein (Hsp) 70 and prevent TNF-induced apoptosis. [32] [33] [34] These subtle changes likely account for the lack of specificity exhibited by U266 10 cells, for example, their failure to induce paralysis.
Modulating mtDNA copy in GBM cells affects tumorigenic gene expression To determine whether the changes in gene expression resulting from the replenishment of mtDNA copy number to promote tumorigenesis were more widespread, we analysed our GBM tumour model. There were 101 differentially expressed genes between GBM 0.2 and GBM 3 tumours and GBM 100 tumours with the most affected networks being: (1) cellular development, cellular growth and proliferation, and haematological system development and function; (2) cancer, gastrointestinal disease, and organismal injury and abnormalities; (3) and cancer, organismal injury and abnormalities, and reproductive system disease (Supplementary Table S7 ). The increased expression of genes associated with B-cell receptor signalling and the cytoskeleton likely promoted cell proliferation and tumour formation, [35] [36] [37] [38] [39] Comparison of the more aggressive GBM 50 tumours and GBM 100 tumours identified 136 differentially expressed genes. The cancer, cell cycle, cellular development; skeletal and muscular system development and function, skeletal and muscular disorders, cardiovascular system development and function; and connective tissue disorders, cellular assembly and organization, ; greendownregulated in U266 10 , fold change 42, Po 0.05).
cellular function and maintenance were the most affected networks (Supplementary Table S8 ). Of the affected genes, 12 were cancer specific (Supplementary Extended Data Figure S3 ; P o0.05), which included a key regulator of autophagy, hypoxiarelated genes and a modulator of the Wnt/β-catenin signalling pathway. Collectively, these changes in gene expression promote migration and invasion of tumour cells.
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DISCUSSION
Our data demonstrate that mtDNA is an essential driver of tumorigenesis. Indeed, a tumour cell's mtDNA content undergoes dynamic changes during tumorigenesis, which likely reflects changes in the aerobic nature of the microenvironment and the cell's requirement for ATP derived from OXPHOS. In our three models, copy number is modulated at early and late progression and, in GBM and osteosarcoma, this is matched by changes in regions of the genome susceptible to variants. The Complex I gene, ND6, is the most affected, which is the only protein coding gene on the light strand and is the last of these genes to be replicated, 43 and is thus most prone to the proofreading error that affects POLGA. 44 As ND6 is essential to assembly and function of Complex I, its dysfunction would therefore promote a shift to glycolysis for ATP generation. 45 In addition, hypermethylation of POLGA limits the numbers of mtDNA copy available for transcription, thus further promoting aerobic glycolysis. Nevertheless, cells lacking mtDNA have the potential to initiate tumorigenesis by acquiring it from the surrounding stroma. However, 143B 0 cells Figure 6 . Differentially expressed genes between GBM 100 and GBM 3 and GBM 0.2 tumours involved in (a) cellular development, (b) cancer and (c) cellular function and maintenance networks (red -upregulated in GBM 3 and GBM 0.2 ; green -downregulated in GBM 3 and GBM 0.2 , fold change 42, P o0.05).
that acquire mouse mtDNA and U266 and GBM cells possessing lower levels of mtDNA are less tumorigenic while those completely depleted cells that do not acquire mtDNA are nontumorigenic and are thus unable to modulate mtDNA to drive tumorigenesis.
Remarkably, in all three models, a tumour cell's mtDNA copy number and genotype can determine the rate of onset for tumorigenesis, morphology and gene expression profiles. Specifically, in our osteosarcoma model, we show that a critical set of genes is present at early progression. While mtDNA haplotypes have been associated with a host of phenotypes and diseases, 46 it is evident that a subset of key genes is recruited at early progression. Other genes, in line with mtDNA copy number and specific to haplotype, would be recruited to promote transition to late progression in order to define the tumours end point phenotype. Consequently, targeting mtDNA and commonly expressed early tumour-specific genes would provide novel candidate approaches against tumour formation. 
MATERIALS AND METHODS
Cell lines and viral transduction
The human myeloma cell line U266 was obtained from ATCC (Manassas, VA, USA) and maintained in single-cell suspensions in RPMI 1640 media supplemented with 10% fetal bovine serum (FBS), 2 mM GlutaMax and 1 mM sodium pyruvate (all from Gibco Life Technologies, Carlsbad, CA, USA). U266 cells suitable for bioluminescent imaging were transduced by spinfection in the presence of 4 μg/ml polybrene and supernatant containing lentiviral particles with the FUL2-TG vector kindly provided by Dr. Marco Herold (Walter and Eliza Hall Institute, Melbourne, Australia). The FUL2-TG vector contains luciferase-2 and GFP driven by the ubiquitin promoter. 47 GFP+ cells were sterile sorted prior to transplant using an Influx cell sorter (Becton Dickinson, North Ryde, NSW, Australia).
Culture of multiple myeloma cell lines U266 cells were cultured in single-cell suspensions in RPMI 1640 media supplemented with 10% FBS, 2 mM GlutaMax and 1 mM sodium pyruvate (all from Life Technologies, Carlsbad, CA, USA). MtDNA depletion was performed by the addition of 10μg/ml of 2′,3′-dideoxycytidine (ddC), in the presence of 50μg/ml of uridine (both from Sigma, St Louis, MO, USA). For the recovery of mtDNA, cells were cultured in complete RPMI media in the absence of ddC, or in the presence of the glycolysis inhibitor, 2-deoxyglucose (2-DG), at a concentration of 5 mM Culture of osteosarcoma (143BTK − ) cell lines Human osteosarcoma (143B) cells, which were deficient in thymidine kinase activity (143BTK − ) and 143B 0 cells, which were previously completely depleted of mtDNA by long-term exposure of ethidium bromide, 10, 11 were kindly donated by Assoc Prof. Ian Trounce, Centre for Eye Research, Australia. All 143BTK − cell lines were routinely cultured in standard DMEM (SD-DMEM) consisting of DMEM, 10% (v/v) FBS, 10 mM sodium pyruvate, 2 mM GlutaMax and 1% (v/v) penicillin/streptomycin (Life Technologies). 143B 0 cells were supplemented with uridine (SigmaAldrich, Sydney, NSW, Australia) at a final concentration of 50 μg/ml. All cell lines were cultured at 37°C in 5% CO 2 and 95% humidity.
Generation of 143B
NSC and 143B GBM cells 143B 0 cells were repopulated with donor mtDNA through fusion with cytoplasts from human neural stem cells (hNSC) derived from the embryonic stem cell line WA09 and human glioblastoma multiforme cells (HSR-GBM1) to generate trans-mitochondrial cybrids, according to methods previously described. 48 In brief, 3 × 10 6 hNSC, HSR-GBM1 cells were each resuspended in 10 ml of SD-DMEM and mixed with 10 ml of Percoll solution (Sigma) pre-warmed at 37°C, 200 μl penicillin/streptomycin and 2 mg/ml cytochalasin B (Sigma) in 50 ml Nalgene high-speed centrifuge tubes (Nalgene, Waltham, MA, USA). Cells were centrifuged at 20 000 r.p.m. using a SS-34 fixed angle rotor for 70 min at 27°C to enucleate. Percoll/media interface (7.5 ml) was transferred to 15 ml tubes and 7.5 ml of fresh SD-DMEM was added to the cell suspension and centrifuged at 4400 r.p.m. for 5 min. Following centrifugation, the supernatant was removed and the cell pellets were resuspended in 10 ml of SD-DMEM. 1 × 10 6 143B 0 cells were mixed with 10 ml cell suspension of hNSCs or HSR-GBM1 cells in 50 ml Nalgene high-speed centrifuge tubes and centrifuged at 10 000 r.p.m. using the SS-34 fixed angle rotor at 27°C for 10 min. Cell pellets were collected and covered with 500 μl of cell culture grade polyethylene glycol (PEG; Sigma) for 1 min. PEG was immediately removed and the cell pellets were resuspended in 10 ml of SD-DMEM to complete fusion.
The fusion mixtures were then cultured in SD-DMEM for 24 h at 37°C in 5% CO 2 and 95% humidity and transferred to the selection media, CSM, consisting of RPMI medium (Life Technologies), 5% FBS, 2 mM GlutaMax, 1% penicillin/streptomycin and 5-bromo-2-deoxyuridine (BrdUrd; Sigma) at a final concentration of 20 μg/ml. The medium was replaced every 2 days. After 7-14 days, propagated cell colonies were isolated and expanded in CSM media. The fused cells containing mtDNA from hNSCs and HSR-GBM1 were named as 143B NSC and 143B GBM , respectively.
MtDNA genotyping
MtDNA genotyping was subsequently performed using capillary sequencing to confirm transfer of desired mtDNA populations into the recipient 143B 0 cells. Purified DNA from control 143BTK − (143B 100 ), 143B 0 , 143B NSC and 143B GBM was amplified using conventional PCR with primers that amplify the human D-Loop region (Table 1) . PCR products were confirmed on 2% agarose gels (Bioline, Sydney, NSW, Australia) and the desired bands were excised and purified using the QIAquick Gel Extraction Kit (Qiagen, Valencia, CA, USA). Samples were sequenced through the Monash Health Translational Precinct (MHTP) Medical Genomics Facility (Hudson Institute of Medical Research, Clayton, VIC, Australia) using the automated Applied Biosystems 3130xl Genetic Analyzer and the Applied Biosystems BigDye Terminator 3.1 reaction kit (Applied Biosystems, Carlsbad, CA, USA). Sequence files were analysed using the software 4 Peaks (v1.7.1) (mekentosj.com) and Basic Local Alignment Tool (BLAST; NCBI; http:// blast.ncbi.nlm.nih.gov) to confirm that the correct sequences were amplified. The sequences were further aligned using the ClustalW2 alignment software tool (EMBL, Germany) and UGENE 49 multiple alignment tool to generate a phylogenetic tree.
Generation of MM xenografts and bioluminescent imaging 2.5 × 10 5 U266 cells were transplanted into NSG mice by tail vein injection. Mice were imaged using a Lumina III XR bioluminescent imaging system (Perkin Elmer, Waltham, MA, USA) starting at 4 weeks post-transplant. Briefly, mice were injected intraperitoneally with sufficient luciferin (Perkin Elmer) for a final concentration of 30 mg/kg. After 10 min, mice were anaesthetized by inhalation of isofluorane and placed in the instrument. To acquire and analyse bioluminescent data, Living Image software (Perkin Elmer) was used. Regions of interest were drawn to encompass the entire mouse and total flux data were recorded.
Post-mortem FACS sorting of donor cells for analysis
Following final imaging at 11 weeks post-transplantation, NSG mice that received undepleted and 7-day depleted U266 cells were killed. Bone marrow from both femurs and tibiae was obtained by flushing with PBS. The spine was isolated from the mouse and marrow cells were obtained by crushing the spine in a 40 μm cell strainer (Falcon, Fisher Biotec, Wembley, WA, Australia) using the rubber end of a 5-ml syringe plunger (Falcon, Fisher Biotec). Following red blood cell lysis, cells were stained with APCconjugated anti-human CD138 (Miltenyi, Bergisch Gladbach, Germany).
All GFP+ and/or CD138+ cells were collected by FACS sorting on a FACS Aria (BD). Collected cells were centrifuged, the supernatant was removed and the cell pellet was snap frozen for subsequent analyses.
143B xenografts
Female BALB/c Nude mice, 6-8 weeks of age, received right flank injections of 1x10 6 cells/mouse in 200 μl of 1 : 1 mixed cell suspension and Matrigel. Tumour size was measured using digital calipers and volumes were calculated according to the formula: tumour volume (mm 3 ) = (width 2 × length)/2. Mouse body weight and tumour volumes were measured daily. Experiments were terminated once tumour size exceeded 800mm 3 or in the absence of tumour development 5 months post-inoculation. At end point, mice were killed by cervical dislocation, tumours were excised using aseptic techniques and divided for histology, RNA and DNA extraction, or cell sorting.
Histology
Tumours were fixed in 10% neutral-buffered formalin for 24 h and changed into 70% ethanol before processing into paraffin. Parrafinembedded tumour sections were analysed by histology after generating 4 μm sections and staining with haematoxylin and eosin.
Isolation of tumour cells by flow cytometry
Established heterogeneous tumour cell lines were sorted according to viability, singlets and cell size. Briefly, the heterogeneous cell suspension was incubated in LIVE/DEAD Fixable Violet Dead Cell Stain Kit (Life Technologies; L34955) to distinguish viable and dead cells and analysed by flow cytometry using the Mo-Flo BTA analyzer. Following gating for viable cells and singlets, three populations of cells were identified based on cell size. All three populations were individually isolated for analysis.
DNA and RNA extraction
Total DNA and RNA were extracted using the DNeasy Blood and Tissue Kit (Qiagen) and RNeasy Mini Kit (Qiagen), respectively, according to the manufacturer's instructions. The DNA samples were treated with RNase A solution (Qiagen) and Proteinase K Solution (Qiagen) at 65°C for 10 min and RNA samples were treated with DNase I (Qiagen) for 20 min at room temperature.
Reverse transcriptase PCR cDNA was synthesized, according to the manufacturer's instructions, using the Superscript III First-Strand Synthesis System (Life Technologies). β-Actin was chosen as the housekeeping gene to normalize the expression results following the real-time PCR (Supplementary Table S9 ).
Real-time PCR: mtDNA copy number and mRNA expression analysis Real-time PCR (quantitative PCR, qPCR) was performed on purified total DNA using the Rotor-Gene 3000 (Corbett Research, Cambridge, UK). Two microliters of DNA template were mixed with 10 μl of 2X SensiMix (Bioline), 1 μl of each forward and reverse primers (Sigma) (Supplementary Table S9 ) at a concentration of 5 μM and 6 μl distilled water to a final volume of 20 μl. The number of mtDNA copies/cells and relative expression levels of POLGA were quantified against external standards of β-globin and mtDNA, using real-time PCR, as previously described.
14 mRNA expression levels were determined by the ΔΔCt method, as described. 14 
Gene expression microarray analysis
Purified total RNA from both early and late progression tumours derived from each 143B cell line was labelled, amplified and hybridized to HumanHT-12 v4 Expression BeadChip Kit (Illumina, Scoresby, VIC, Australia) in triplicate though the Australian Genome Research Facility Ltd (AGRF; Walter Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia), according to the manufacturer's protocols. Expression data were analysed using GenomeStudio Gene Expression Module (Illumina) and the limma package of R Bio-conductor 50 (http://www.r-project.org).
Immunoprecipitation of methylated DNA (MeDIP) analysis MeDIP was performed, as previously described, 14 with minor modifications. Purified DNA was fragmented to sizes between 200-1000 bp using the S220 Focused-ultrasonicator (Covaris, Woburn, MA, USA) and the software SonoLab 7 (Covaris). Fragmented DNA was denatured at 95°C for 10 min and cooled on ice for 5 min. Following denaturation, 3 μg of single-stranded DNA fragments were incubated with 2 μg of either anti-5-methylcytosine (5mC; Active Motif, Carlsbad, CA, USA) or anti-5-hydroxymethylcytosine (5hmC; Active Motif) antibodies with 20 μl of Protein G Dynabeads (Invitrogen, Carlsbad, CA, USA) in 500 μl of IP buffer, consisting of 10 mM sodium phosphate, pH 7.0, 140 mM sodium chloride and 0.05% (v/v) Triton X-100, at 4°C overnight. Samples were washed three times with 700 μl IP buffer after overnight incubation. Immunoprecipitated DNA was released from the beads and eluted in 250 μl of Proteinase K digestion buffer, consisting of 5 mM Tris, 1 mM EDTA, pH8.0, 0.05% SDS with the addition of 7 μl of Proteinase K (20 μg/μl; Qiagen) while rotating at 50°C for 3 h. DNA samples were purified using phenolchloroform and precipitated with 3 μg of glycogen (Invitrogen) and 100% ethanol at − 80°C for a minimum of 2 h. DNA pellets were further washed with 70% ethanol and resuspended in distilled water.
mtDNA next generation sequencing
Templates for next generation sequencing were generated by long PCR amplification of two overlapping fragments that cover the entire mitochondrial genome. The PCR reactions were prepared with 1 × High Fidelity PCR buffer, 100 mM MgSO 4 , 1U of Platinum Taq High Fidelity (Invitrogen), 1 mM dNTPs (Bioline) and 10 μM each of forward and reverse primers (Supplementary Table S9 ). PCR products were purified using the QIAquick PCR Purification Kit (Qiagen).
Purified amplicons from both long PCR reactions were combined at equal concentrations and used to generate amplicon libraries using the Ion Fragment Library kit and the Ion Express Template kit (Life Technologies), according to the manufacturer's instructions. Libraries were loaded onto 318 chips for sequencing on an Ion Torrent Personal Genomic Machine (PGM). Sequences were then aligned to the reference sequence using CLC Genomic Workbench (v5.5.1). Variant selection was performed using CLC Genomic Workbench (v5.5.1), as previously described. 28 For detection of variants, a minimum mutation threshold of 3% was applied prior to analysis.
RNA sequencing
An Agilent Bioanalyser Nanochip (Agilent, Melbourne, VIC, Australia) was used for quality control of total RNA. cDNA libraries were synthesized and prepared using the Illumina Truseq Stranded mRNA Kit (Illumina), according to the manufacturer's instructions. cDNA libraries were then sequenced using the HiSeq 2000 sequencing system (Illumina) at AGRF. The primary sequence data were generated using the Illumina CASAVA 1.8.2 pipeline. The sequence reads were aligned against the Homo sapiens genome (Build version HG19) and mapped using the Tophat aligner (v1.3.1; http://ccb.jhu.edu/software/tophat/manual.shtml). The transcripts were assembled and tested for differential expression using the Cufflinks tool (v2.2.1; http://cole-trapnell-lab.github.io/cufflinks/).
Computational pathway analysis
Normalized expression data generated from both microarray and RNA-seq were uploaded into Ingenuity Pathway Analysis software (IPA; Qiagen). Expression data from the microarray were analysed with cutoffs of a foldchange in expression over 2 and Po 0.05. The same cutoffs were applied to the RNA-seq data with the addition of the false discovery rate (q-value) o0.05. The selected genes were then mapped against the inbuilt KEGG pathways for selection of the most affected canonical pathways and networks.
Statistics analysis
Graphical output and statistical analyses were performed using the Prism 5 software package version 5.0d (GraphPad Software, San Deigo, CA, USA). One-way ANOVA was used followed by Bonferroni post hoc tests. Significance was considered when Po 0.05. All data are represented as mean ± S.E.M. Mitochondrial genome sequence data for 143B  100 , 143B  NSC and  143B GBM cells have been deposited in the GenBank nucleotide core database under the accession codes KT946592, KT946593 and KT946594. Next generation sequencing data for the mitochondrial genomes of all 143B and U266 samples have been deposited in the NCBI Sequence Read Archive (SRA) under the accession code PRJNA29 5347. RNA sequencing data for all U266 and HSR-GBM1 samples have been deposited in the NCBI Sequence Read Archive (SRA) under the accession code PRJNA296542. Illumina gene expression microarray data for all 143B samples have been deposited in the Gene Expression Omnibus (GEO) database under the accession code GSE73120.
DATA DEPOSITION
AUTHOR CONTRIBUTIONS
WTYL performed experiments and data analysis, contributed to the experimental design and wrote the manuscript. JEC and AC performed inoculation and collection of tumours and data analysis, and contributed to writing the manuscript. JJ, AD and K-YY performed cell culture, data analysis and contributed to the experimental design. BK performed tumour histology assessment analysis and interpretation. TGJ, DNW and AS contributed to designing the experiments, performed data analysis, contributed to writing the manuscript and obtained funding for the work. JCS designed the experiments, performed data analysis, wrote the manuscript and obtained funding for the work. All authors discussed the results and commented on the manuscript.
